Posted by Michael Wonder on 12 Aug 2022
NICE recommendation expands patient eligibility for AbbVie’s Ozurdex
12 August 2022 - Treatment becomes an option for treating visual impairment caused by diabetic macular oedema, regardless of lens status.
AbbVie has announced that NICE has issued a final appraisal document recommending the dexamethasone intravitreal implant – also known as Ozurdex – as a treatment option within the NHS, for adults with visual impairment caused by diabetic macular oedema.
